At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Nov 20, 2026 at 10:30 ET
PMV Pharma reported positive Phase 2 data for rezatapopt in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer, with a 48% ORR and 10.4-month median duration of response in the primary analysis population. The company plans to submit an NDA for accelerated approval in Q1 2027.
- 48% confirmed ORR in primary analysis of 65 platinum-resistant/refractory ovarian cancer patients
- 10.4-month median duration of response in primary analysis population
- 36% ORR across all 168 evaluable patients in overall population
- NDA submission for accelerated approval planned in Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access